<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.deals.v2.DealRecordsOutput xmlns:ns2="local"><serviceExecutionTime>258</serviceExecutionTime><Deal id="118525"><Title>Chiron to market DepoTech's DepoCyt in the US, Canada and Europe </Title><CompanyPrincipal id="26338">Pacira BioSciences Inc</CompanyPrincipal><CompanyPartner id="15385">Chiron Corp</CompanyPartner><Type>Drug - Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="&gt;" max="28.4" min="28.4"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Payment Unspecified" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Unknown" max="0.0" min="0.0"></ValueProjected></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>249306</Reference><Type>Undisclosed</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="5.2" usdExchangeRate="1.0" usdExchangeRatePeriod="1993 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Loan/Credit</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1993 Q4">11.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Profit Split(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1993 Q4">50.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Transfer Price(%)</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Profit Split(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1993 Q4">50.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1993 Q4">11.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Loan/Credit</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Transfer Price(%)</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="3.5" usdExchangeRate="1.0" usdExchangeRatePeriod="1993 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="5.5" usdExchangeRate="1.0" usdExchangeRatePeriod="1993 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="3.5" usdExchangeRate="1.0" usdExchangeRatePeriod="1993 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="5.5" usdExchangeRate="1.0" usdExchangeRatePeriod="1993 Q4">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="5.2" usdExchangeRate="1.0" usdExchangeRatePeriod="1993 Q4">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="651">Cancer</Indication></Indications><Technologies><Technology id="589">Sustained release formulation</Technology></Technologies><DateStart>1994-03-31T00:00:00Z</DateStart><DateEnd>2002-12-31T00:00:00Z</DateEnd><DateEventMostRecent>2002-12-31T00:00:00Z</DateEventMostRecent><Drugs><Drug id="9049"><DrugNameDisplay>cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="L">Launched</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In March 1994, a collaborative agreement with DepoTech (subsequently SkyePharma; now &lt;ulink linkType="Company" linkID="26338"&gt;Pacira Pharmaceuticals&lt;/ulink&gt;)  granted &lt;ulink linkType="Company" linkID="15385"&gt;Chiron&lt;/ulink&gt; (now a part of &lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt;)  rights to market and sell &lt;ulink linkType="Drug" linkID="9049"&gt;DepoCyt&lt;/ulink&gt; in the US, Canada and Europe [&lt;ulink linkType="Reference" linkID="249306"&gt;249306&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1852973"&gt;1852973&lt;/ulink&gt;]. In June 1997, DepoTech repurchased marketing rights to DepoCyt for Europe and Canada [&lt;ulink linkType="Reference" linkID="249306"&gt;249306&lt;/ulink&gt;]. By December 2002, SkyePharma had reacquired US rights from Chiron [&lt;ulink linkType="Reference" linkID="475307"&gt;475307&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>1994-03-31T00:00:00Z</Date><Drugs><DrugLink id="9049" nameDisplay="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"></DrugLink></Drugs><Stage id="DR">Discovery</Stage><Summary>&lt;para&gt;In March 1994, a collaborative agreement with DepoTech (subsequently SkyePharma; now &lt;ulink linkType="Company" linkID="26338"&gt;Pacira Pharmaceuticals&lt;/ulink&gt;)  granted &lt;ulink linkType="Company" linkID="15385"&gt;Chiron&lt;/ulink&gt; (now a part of &lt;ulink linkType="Company" linkID="23137"&gt;Novartis&lt;/ulink&gt;)  rights to market and sell &lt;ulink linkType="Drug" linkID="9049"&gt;DepoCyt&lt;/ulink&gt; in the US, Canada and Europe. &lt;/para&gt;&lt;para&gt;- The deal  was worth $14.2 million [&lt;ulink linkType="Reference" linkID="249306"&gt;249306&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1852973"&gt;1852973&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>1997-06-06T00:00:00Z</Date><Drugs><DrugLink id="9049" nameDisplay="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"></DrugLink></Drugs><PaymentsToPartner><Payment><Reference id="249306">249306</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="2">Payment Unspecified</Accuracy></Value></Payment></PaymentsToPartner><Summary>&lt;para&gt;In June 1997, DepoTech repurchased marketing rights to DepoCyt for Europe and Canada. Chiron was to retain exclusive marketing rights to DepoCyt in the US, and was to continue to share in the funding of clinical trials of DepoCyt in the US. DepoTech would  make an upfront payment to Chiron [&lt;ulink linkType="Reference" linkID="249306"&gt;249306&lt;/ulink&gt;]. &lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2002-12-31T00:00:00Z</Date><Drugs><DrugLink id="9049" nameDisplay="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"></DrugLink></Drugs><Summary>&lt;para&gt;By December 2002, SkyePharma had reacquired US marketing, distribution and sales rights from Chiron [&lt;ulink linkType="Reference" linkID="475307"&gt;475307&lt;/ulink&gt;]. &lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event></TimeLine><Patents><Patent id="IN2683893"><Number>US-05422120</Number><Title>Heterovesicular Liposomes</Title></Patent></Patents><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="9049" type="Drug"><TargetEntity id="280234" type="siDrug">Liposomal cytarabine</TargetEntity></SourceEntity><SourceEntity id="15385" type="Company"><TargetEntity id="5036161975" type="organizationId">Chiron Corp</TargetEntity></SourceEntity><SourceEntity id="26338" type="Company"><TargetEntity id="4297853578" type="organizationId">Pacira Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="121174"><Title>Sankyo to develop Ligand's ilomastat for ophthalmic use in the Far East and Japan</Title><CompanyPrincipal id="17808">Ligand Pharmaceuticals Inc</CompanyPrincipal><CompanyPartner id="19658">Sankyo Co Ltd</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="1.0" min="1.0"></ValuePaid><ValueProjected accuracy="=" max="34.85" min="34.85"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Unknown" max="0.0" min="0.0"></ValueProjected></ValuesToPartner><TerritoriesIncluded><Territory id="XH">Far East</Territory><Territory id="JP">Japan</Territory></TerritoriesIncluded><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1994 Q1">10.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1994 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Transfer Price(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1994 Q1">17.5</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="3.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1994 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Transfer Price(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1994 Q1">17.5</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Payment</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="0.15" usdExchangeRate="1.0" usdExchangeRatePeriod="1994 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1994 Q1">10.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="8.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1994 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="8.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1994 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="5.85" usdExchangeRate="1.0" usdExchangeRatePeriod="1994 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="3.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1994 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="5.85" usdExchangeRate="1.0" usdExchangeRatePeriod="1994 Q1">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="573">Corneal ulcer</Indication><Indication id="239">Ocular disease</Indication></Indications><ActionsPrimary><Action id="2460">Metalloprotease-1 inhibitor</Action><Action id="253">Matrix metalloprotease inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="2657">Antihypertensive</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="1053">Carbohydrate</Technology></Technologies><DateStart>1994-06-27T00:00:00Z</DateStart><DateEnd>1999-08-03T00:00:00Z</DateEnd><DateEventMostRecent>1999-08-03T00:00:00Z</DateEventMostRecent><Drugs><Drug id="5455"><DrugNameDisplay>ilomastat</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DX">Discontinued</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In June 1994, &lt;ulink linkType="Company" linkID="19658"&gt;Sankyo&lt;/ulink&gt; had acquired rights to &lt;ulink linkType="Company" linkID="17808"&gt;Ligand&lt;/ulink&gt; (formerly &lt;ulink linkType="Company" linkID="17809"&gt;Glycomed&lt;/ulink&gt;)'s &lt;ulink linkType="Drug" linkID="5455"&gt;ilomastat&lt;/ulink&gt; for ophthalmic use in the Far East and Japan [&lt;ulink linkType="Reference" linkID="165238"&gt;165238&lt;/ulink&gt;]. By August 1999, Sankyo had terminated its licensing agreement [&lt;ulink linkType="Reference" linkID="334896"&gt;334896&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>1994-08-30T00:00:00Z</Date><Drugs><DrugLink id="5455" nameDisplay="ilomastat"></DrugLink></Drugs><PaymentsToPrincipal><Payment><Reference id="1646155">1646155</Reference><Type>Upfront Payment</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="1994 Q2" exchangeRateUS="1">1</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="DR">Discovery</Stage><Summary>&lt;para&gt;In June 1994, &lt;ulink linkType="Company" linkID="19658"&gt;Sankyo&lt;/ulink&gt; had acquired rights to &lt;ulink linkType="Company" linkID="17808"&gt;Ligand&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="17809"&gt;Glycomed&lt;/ulink&gt;)'s &lt;ulink linkType="Drug" linkID="5455"&gt;ilomastat&lt;/ulink&gt; for ophthalmic use in the Far East and Japan. Ligand retained manufacturing rights. No financial terms were disclosed [&lt;ulink linkType="Reference" linkID="165238"&gt;165238&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>1999-08-03T00:00:00Z</Date><Drugs><DrugLink id="5455" nameDisplay="ilomastat"></DrugLink></Drugs><Summary>&lt;para&gt;By August 1999, Sankyo had terminated its licensing agreement and discontinued development of the compound [&lt;ulink linkType="Reference" linkID="334896"&gt;334896&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event></TimeLine><Patents><Patent id="IN2146626"><Number>US-05183900</Number><Title>Matrix Metalloprotease Inhibitors</Title></Patent></Patents><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="5455" type="Drug"><TargetEntity id="194637" type="siDrug">Ilomastat</TargetEntity></SourceEntity><SourceEntity id="19658" type="Company"><TargetEntity id="5000284515" type="organizationId">Sankyo Co Ltd Pharmaceutical</TargetEntity></SourceEntity><SourceEntity id="17808" type="Company"><TargetEntity id="4295907009" type="organizationId">Ligand Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="239" type="ciIndication"><TargetEntity id="10015916" type="MEDDRA"></TargetEntity><TargetEntity id="D005128" type="MeSH"></TargetEntity><TargetEntity id="-2056365523" type="omicsDisease"></TargetEntity><TargetEntity id="754" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="573" type="ciIndication"><TargetEntity id="H16.0" type="ICD10"></TargetEntity><TargetEntity id="D003320" type="MeSH"></TargetEntity><TargetEntity id="-1247959915" type="omicsDisease"></TargetEntity><TargetEntity id="771" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="253" type="Action"><TargetEntity id="451" type="Mechanism">Matrix Metalloproteinase Inhibitors</TargetEntity><TargetEntity id="1087" type="Mechanism">Metalloprotease Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2460" type="Action"><TargetEntity id="454" type="Mechanism">MMP-1 (Interstitial Collagenase) Inhibitors</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="122019"><Title>Cerebrus and Eli Lilly to codevelop VML-670 for CNS-related indications</Title><CompanyPrincipal id="17810">Eli Lilly &amp; Co</CompanyPrincipal><CompanyPartner id="19993">Vernalis Research Ltd</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="&gt;" max="5.0" min="5.0"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Unknown" max="0.0" min="0.0"></ValueProjected></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1998 Q2">10.0</ReportedAmountMil></Value></Payment><Payment><Reference>402399</Reference><Type>Royalty Payment</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1998 Q2">10.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="2.5" usdExchangeRate="1.0" usdExchangeRatePeriod="1998 Q2">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>402399</Reference><Type>Other Milestones</Type><Value accuracy="Payment Unspecified"></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="2.5" usdExchangeRate="1.0" usdExchangeRatePeriod="1998 Q2">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="60">Central nervous system disease</Indication><Indication id="110">Emesis</Indication><Indication id="369">Male sexual dysfunction</Indication></Indications><ActionsPrimary><Action id="6">5-HT 1a receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2970">Anti-emetic</Action><Action id="2939">CNS modulator</Action></ActionsSecondary><Technologies><Technology id="1102">Synthetics deal</Technology><Technology id="1099">In-licensed product deal</Technology></Technologies><DateStart>1998-09-14T00:00:00Z</DateStart><DateEnd>2003-10-01T00:00:00Z</DateEnd><DateEventMostRecent>2003-10-01T00:00:00Z</DateEventMostRecent><Drugs><Drug id="19955"><DrugNameDisplay>VML-670</DrugNameDisplay><PhaseHighestStart id="PC">Preclinical</PhaseHighestStart><PhaseHighestNow id="DX">Discontinued</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In September 1998, Cerebrus (now &lt;ulink linkType="Company" linkID="19993"&gt;Vernalis&lt;/ulink&gt;) and &lt;ulink linkType="Company" linkID="17810"&gt;Eli Lilly&lt;/ulink&gt; entered a joint development agreement for &lt;ulink linkType="Drug" linkID="19955"&gt;VML-670&lt;/ulink&gt; for a number of CNS-related indications [&lt;ulink linkType="Reference" linkID="298312"&gt;298312&lt;/ulink&gt;]. In October 2003, Vernalis decided to discontinue development of  the compound, and it was assumed that the deal was also terminated [&lt;ulink linkType="Reference" linkID="507274"&gt;507274&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>1998-09-14T00:00:00Z</Date><Drugs><DrugLink id="19955" nameDisplay="VML-670"></DrugLink></Drugs><Stage id="PC">Preclinical</Stage><Summary>&lt;para&gt;In September 1998, Cerebrus (now &lt;ulink linkType="Company" linkID="19993"&gt;Vernalis&lt;/ulink&gt;) and &lt;ulink linkType="Company" linkID="17810"&gt;Eli Lilly&lt;/ulink&gt; entered a joint development agreement for &lt;ulink linkType="Drug" linkID="19955"&gt;VML-670&lt;/ulink&gt; for a number of CNS-related indications, including delayed and anticipatory emesis associated with cancer chemotherapy. Cerebrus was to undertake clinical development up to the end of phase II trials; Lilly retained the option to commercialize the product or allow Cerebrus to undertake phase III development, registration and marketing. No financial terms were disclosed [&lt;ulink linkType="Reference" linkID="298312"&gt;298312&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>2001-03-19T00:00:00Z</Date><Drugs><DrugLink id="19955" nameDisplay="VML-670"></DrugLink></Drugs><Summary>&lt;para&gt;In March 2001, the agreement was amended to include the investigation of the compound for the treatment of sexual dysfunction in patients taking SSRI's. Vernalis was to develop the compound for this indication to proof-of-principle in patients and Lilly would then have the right to complete development and commercialize the compound, in return for milestone and royalty payments [&lt;ulink linkType="Reference" linkID="402399"&gt;402399&lt;/ulink&gt;]. &lt;/para&gt;</Summary><Type>Deal Amendment</Type></Event><Event><Date>2003-10-01T00:00:00Z</Date><Drugs><DrugLink id="19955" nameDisplay="VML-670"></DrugLink></Drugs><Summary>&lt;para&gt;In October 2003, following disappointing phase II results, Vernalis decided to discontinue development of  the compound, and it was assumed that the deal was also terminated [&lt;ulink linkType="Reference" linkID="507274"&gt;507274&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event></TimeLine><Patents><Patent id="IN1042511"><Number>US-04576959</Number><Title>6-Substituted-4-Dialkylaminotetrahydrobenz(C,D)Indoles</Title></Patent></Patents><IsOptional>Y</IsOptional><CrossReferences><SourceEntity id="19955" type="Drug"><TargetEntity id="274101" type="siDrug">CEB-1555</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="19993" type="Company"><TargetEntity id="4296652737" type="organizationId">Vernalis Research Ltd</TargetEntity></SourceEntity><SourceEntity id="110" type="ciIndication"><TargetEntity id="R11.1" type="ICD10"></TargetEntity><TargetEntity id="10047700" type="MEDDRA"></TargetEntity><TargetEntity id="D014839" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="369" type="ciIndication"><TargetEntity id="10057672" type="MEDDRA"></TargetEntity><TargetEntity id="364" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="60" type="ciIndication"><TargetEntity id="D002493" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="6" type="Action"><TargetEntity id="220" type="Mechanism">5-HT1A Receptor Agonists</TargetEntity></SourceEntity></CrossReferences></Deal><Deal id="125082"><Title>Eli Lilly to develop Ophidian's OPHD-001 for gastrointestinal infections</Title><CompanyPrincipal id="18684">Ophidian Pharmaceuticals Inc</CompanyPrincipal><CompanyPartner id="17810">Eli Lilly &amp; Co</CompanyPartner><Type>Drug - Development/Commercialization License</Type><Status>Terminated</Status><ValuesToPrincipal><ValuePaid accuracy="=" max="1.0" min="1.0"></ValuePaid><ValueProjected accuracy="=" max="24.8" min="24.8"></ValueProjected></ValuesToPrincipal><ValuesToPartner><ValuePaid accuracy="Unknown" max="0.0" min="0.0"></ValuePaid><ValueProjected accuracy="Unknown" max="0.0" min="0.0"></ValueProjected></ValuesToPartner><PaymentsProjected><PaymentsToPrincipal><Payment><Reference>1646155</Reference><Type>Transfer Price(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1996 Q1">23.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1996 Q1">5.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Transfer Price(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1996 Q1">23.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Royalty(%)</Type><Value accuracy="="><ReportedAmountMil usdExchangeAmount="0.0" usdExchangeRate="0.0" usdExchangeRatePeriod="1996 Q1">5.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="0.4" usdExchangeRate="1.0" usdExchangeRatePeriod="1996 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="11.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1996 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>298476</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1996 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>Dev/Reg Milestones</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="11.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1996 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>298476</Reference><Type>Upfront Equity</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="1.0" usdExchangeRate="1.0" usdExchangeRatePeriod="1996 Q1">0.0</ReportedAmountMil></Value></Payment><Payment><Reference>1646155</Reference><Type>R&amp;D Funding</Type><Value accuracy="="><ReportedAmountMil reportedCurrency="USD" usdExchangeAmount="0.4" usdExchangeRate="1.0" usdExchangeRatePeriod="1996 Q1">0.0</ReportedAmountMil></Value></Payment></PaymentsToPrincipal></PaymentsProjected><Indications><Indication id="577">Gastrointestinal infection</Indication><Indication id="40">Bacterial infection</Indication></Indications><ActionsSecondary><Action id="1594">Antibacterial</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="582">Antibody polyclonal</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><DateStart>1996-06-03T00:00:00Z</DateStart><DateEnd>1998-09-15T00:00:00Z</DateEnd><DateEventMostRecent>1998-09-15T00:00:00Z</DateEventMostRecent><Drugs><Drug id="17237"><DrugNameDisplay>OPHD-001</DrugNameDisplay><PhaseHighestStart id="DR">Discovery</PhaseHighestStart><PhaseHighestNow id="DX">Discontinued</PhaseHighestNow></Drug></Drugs><Summary>&lt;para&gt;In June 1996, &lt;ulink linkType="Company" linkID="18684"&gt;Ophidian&lt;/ulink&gt; entered an agreement with &lt;ulink linkType="Company" linkID="17810"&gt;Eli Lilly&lt;/ulink&gt; to develop compounds, including &lt;ulink linkType="Drug" linkID="17237"&gt;OPHD-001&lt;/ulink&gt;, for certain gastrointestinal infections. In September 1998, the collaboration was terminated [&lt;ulink linkType="Reference" linkID="298476"&gt;298476&lt;/ulink&gt;].&lt;/para&gt;</Summary><TimeLine><Event><Date>1996-06-03T00:00:00Z</Date><Drugs><DrugLink id="17237" nameDisplay="OPHD-001"></DrugLink></Drugs><PaymentsToPrincipal><Payment><Reference id="1646155">1646155</Reference><Type>Upfront Equity</Type><Value><Accuracy sortorder="6">=</Accuracy><USDAmountMil exchangeRatePeriod="1996 Q1" exchangeRateUS="1">1</USDAmountMil></Value></Payment></PaymentsToPrincipal><Stage id="DR">Discovery</Stage><Summary>&lt;para&gt;In June 1996, &lt;ulink linkType="Company" linkID="18684"&gt;Ophidian&lt;/ulink&gt; entered an agreement with &lt;ulink linkType="Company" linkID="17810"&gt;Eli Lilly&lt;/ulink&gt; to develop compounds, including &lt;ulink linkType="Drug" linkID="17237"&gt;OPHD-001&lt;/ulink&gt;, for certain gastrointestinal infections. Financial details were undisclosed [&lt;ulink linkType="Reference" linkID="298476"&gt;298476&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Original Deal</Type></Event><Event><Date>1998-09-15T00:00:00Z</Date><Drugs><DrugLink id="17237" nameDisplay="OPHD-001"></DrugLink></Drugs><Summary>&lt;para&gt;In September 1998, the collaboration was terminated [&lt;ulink linkType="Reference" linkID="298476"&gt;298476&lt;/ulink&gt;].&lt;/para&gt;</Summary><Type>Deal Terminated</Type></Event></TimeLine><Patents><Patent id="IN1042204"><Number>US-04569794</Number><Title>Process For Purifying Proteins And Compounds Useful In Such Process</Title></Patent></Patents><IsOptional>N</IsOptional><CrossReferences><SourceEntity id="17237" type="Drug"><TargetEntity id="275938" type="siDrug">OPHD-001</TargetEntity></SourceEntity><SourceEntity id="18684" type="Company"><TargetEntity id="4295914461" type="organizationId">Applied NeuroSolutions Inc</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"></TargetEntity><TargetEntity id="10060945" type="MEDDRA"></TargetEntity><TargetEntity id="D001424" type="MeSH"></TargetEntity><TargetEntity id="-1693440076" type="omicsDisease"></TargetEntity><TargetEntity id="800" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="577" type="ciIndication"><TargetEntity id="10017964" type="MEDDRA"></TargetEntity><TargetEntity id="904" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity></SourceEntity></CrossReferences></Deal></ns2:com.thomsonreuters.ls.service.contract.soap.deals.v2.DealRecordsOutput>